Seguir
Mark D. Berry
Título
Citado por
Citado por
Ano
Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators
MD Berry
Journal of neurochemistry 90 (2), 257-271, 2004
4322004
Apoptotic signaling cascades
PC Ashe, MD Berry
Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2), 199-214, 2003
3122003
Trace amines and their receptors
RR Gainetdinov, MC Hoener, MD Berry
Pharmacological Reviews 70 (3), 549-620, 2018
3022018
The functional role of monoamine oxidases A and B in the mammalian central nervous system
MD Berry, AV Juorio, IA Paterson
Progress in neurobiology 42 (3), 375-391, 1994
2291994
Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges
MD Berry, RR Gainetdinov, MC Hoener, M Shahid
Pharmacology & therapeutics 180, 161-180, 2017
2092017
Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents
PC Ashe, MD Berry, AA Boulton
Progress in Neuro-Psychopharmacology and Biological Psychiatry 25 (4), 691-707, 2001
1622001
Glyceraldehyde‐3‐phosphate dehydrogenase and apoptosis
MD Berry, AA Boulton
Journal of neuroscience research 60 (2), 150-154, 2000
1602000
Aromaticl-amino acid decarboxylase: A neglected and misunderstood enzyme
MD Berry, AV Juorio, XM Li, AA Boulton
Neurochemical research 21, 1075-1087, 1996
1481996
The potential of trace amines and their receptors for treating neurological and psychiatric diseases
MD Berry
Reviews on recent clinical trials 2 (1), 3-19, 2007
1432007
Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
IA Paterson, AV Juorio, MD Berry, MY Zhu
Journal of Pharmacology and Experimental Therapeutics 258 (3), 1019-1026, 1991
991991
Possible mechanisms of action of (−) deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders
MD Berry, AV Juorio, IA Paterson
Progress in neurobiology 44 (2), 141-161, 1994
611994
The effects of administration of monoamine oxidase‐B inhibitors on rat striatal neurone responses to dopamine
MD Berry, E Scarr, MY Zhu, IA Paterson, AV Juorio
British journal of pharmacology 113 (4), 1159-1166, 1994
551994
Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders
MD Berry
Journal of Psychiatry and Neuroscience 29 (5), 337-345, 2004
492004
Prolongation of Life in an Experimental Model of Aging in Drosophila Melanogaster
RG Jordens, MD Berry, C Gillott, AA Boulton
Neurochemical research 24, 227-233, 1999
491999
On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited
A Holt, MD Berry, AA Boulton
Neurotoxicology 25 (1-2), 251-266, 2004
482004
Phosphorylation and Activation of Brain Aromatic l‐Amino Acid Decarboxylase by Cyclic AMP‐Dependent Protein Kinase
AM Duchemin, MD Berry, NH Neff, M Hadjiconstantinou
Journal of neurochemistry 75 (2), 725-731, 2000
432000
Trace amine-associated receptors as novel therapeutic targets for immunomodulatory disorders
SL Christian, MD Berry
Frontiers in Pharmacology 9, 361304, 2018
372018
Membrane permeability of trace amines: Evidence for a regulated, activity‐dependent, nonexocytotic, synaptic release
MD Berry, MR Shitut, A Almousa, J Alcorn, B Tomberli
Synapse 67 (10), 656-667, 2013
372013
Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases
MD Berry, AA Boulton
Neurotoxicology and teratology 24 (5), 667-673, 2002
262002
Loss of mitochondrial membrane potential is dependent on the apoptotic program activated: Prevention by R‐2HMP
D Zhang, MD Berry, IA Paterson, AA Boulton
Journal of neuroscience research 58 (2), 284-292, 1999
231999
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20